Acquired resistance has also been developed to the anti-erbB2 monoclonal antibody Trastuzumab (Herceptin®) in HER2+ breast cancer patients, which seems to be mediated by IGF-1R [259]. Here, ERBB2 is linked to breast carcinoma.